* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocytogen Pharmaceuticals (Beijing) Co Days Payable Chart
Biocytogen Pharmaceuticals (Beijing) Co Annual Data
FRA:I54 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocytogen Pharmaceuticals (Beijing) Co Days Payable vs Biotechnology Industry
Biocytogen Pharmaceuticals (Beijing) Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) has a Days Payable of 125.72 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. This is 58% below median its historical median of 299.93. Over the past decade, Biocytogen Pharmaceuticals (Beijing) Co's Days Payable has ranged from 128.79 to 369.43. According to the industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #323 out of 700 companies in the Biotechnology industry, placing it in the top 46.1%.
Is Biocytogen Pharmaceuticals (Beijing) Co's Days Payable too high?
Biocytogen Pharmaceuticals (Beijing) Co's current Days Payable of 125.72 is 58% below median its 10-year median of 299.93. Over the past 10 years, this metric has ranged from a low of 128.79 to a high of 369.43. The Biotechnology industry median Days Payable is 113.10. Biocytogen Pharmaceuticals (Beijing) Co's value of 125.72 is 11.2% above this industry median. Based on the distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #323 out of 700 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Biocytogen Pharmaceuticals (Beijing) Co has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocytogen Pharmaceuticals (Beijing) Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #323 out of 700 companies for Days Payable. This puts Biocytogen Pharmaceuticals (Beijing) Co in the upper half of its industry. The industry median Days Payable is 113.10. Biocytogen Pharmaceuticals (Beijing) Co's value of 125.72 is 11.2% above this benchmark. Historically, Biocytogen Pharmaceuticals (Beijing) Co's own Days Payable has ranged from 128.79 to 369.43 over the past decade. While the company's 10-year median is 299.93 vs. the industry median of 113.10, Biocytogen Pharmaceuticals (Beijing) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biocytogen Pharmaceuticals (Beijing) Co's current Days Payable of 125.72 is 11.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biocytogen Pharmaceuticals (Beijing) Co's current Days Payable is 125.72, which is 58% below median its own 10-year median of 299.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocytogen Pharmaceuticals (Beijing) Co stock overvalued right now?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.28, compared to a current price of €5.00 — trading 52.4% above its estimated fair value. The current Days Payable is 125.72, which is 58% below median its 10-year median of 299.93 and 11.2% above the Biotechnology industry median of 113.10. Biocytogen Pharmaceuticals (Beijing) Co's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54), the current Days Payable is 125.72 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Overvalued in 2026?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co stock appears to be overvalued.
The current stock price of €5.00 is trading 52.4% above its estimated GF Value™ of €3.28.
GuruFocus considers Biocytogen Pharmaceuticals (Beijing) Co to be Significantly Overvalued.
Key valuation signals for FRA:I54:
Days Payable: 125.72 (58% below median its 10-year median of 299.93)
GF Value™: €3.28 vs. price of €5.00 (52.4% above fair value)
Industry Position: 11.2% above the Biotechnology median (#323 of 700)
No single metric tells the full story. See the FRA:I54 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biocytogen Pharmaceuticals (Beijing) Co Business Description
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
78GF Score
Get the complete analysis for FRA:I54
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:I54 has been successfully added to your 
